Geneva, Dec. 23 -- International Clinical Trials Registry received information related to the study (NCT03096054) titled 'A CR-UK Phase I Trial of LY3143921' on March 15, 2017.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Cancer Research UK
Condition:
A. Colorectal Cancer
B. High Grade Serous Ovarian Cancer
C. Non Small-cell Lung Cancer (squamous Cell Variant)
D. Squamous Carcinoma of the Oesophagus
E. Squamous Carcinoma of the Head and Neck (HPV Negative)
F. Urothelial Cancer
G. Breast Cancer (triple Negative Type)
H. Pancreatic Cancer
Intervention:
Drug: LY3143921 hydrate
Recruitment Status...